Richard A. Ward - Concepedia

Author

Richard A. Ward

Also Known As

David S. Fullerton, J. E. Denne, R A Ward, R. A. WARD, R. A. Ward, R. Ward, R. Østerby, R.A. Ward, RICHARD A. WARD, RICHARD WARD

308

Publications

10.9K

Citations

H-Index

192

Concepts

All Affiliations

University of Louisville AstraZeneca (United Kingdom)University of Cambridge Veterans Health Administration AstraZeneca (United States)

About

Richard A. Ward is an author at University of Louisville specializing in medicine, natural sciences, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	23	42	2.8K
2	Engineering	18	22	1.2K
3	Health Sciences	4	4	171
4	Humanities	1	1	71
5	Law	1	1	71

Richard A. Ward

119

Publications

9.6K

Citations

H-Index

Page 1

	Year	Citations
AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer Darren A.E. Cross, Susan Ashton, Serban Ghiorghiu, Cancer Discovery	2014	2.2K
Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor M. Raymond V. Finlay, Mark J. Anderton, Susan Ashton, Journal of Medicinal Chemistry GeneticsPathologyClinical CandidateTumor BiologyT790m Resistance Mutations	2014	590
Proteomic Analysis of Human Neutrophil Granules George Lominadze, David W. Powell, Greg Luerman, Molecular & Cellular Proteomics	2005	314
Characterization of VPS34-IN1, a selective inhibitor of Vps34, reveals that the phosphatidylinositol 3-phosphate-binding SGK3 protein kinase is a downstream target of class III phosphoinositide 3-kinase Ružica Bago, Nazma Malik, Michael J. Munson, Biochemical Journal Class IiiProteinlipid InteractionMolecular BiologyCellular PhysiologySignaling Pathway	2014	306
Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR) Richard A. Ward, Mark J. Anderton, Susan Ashton, Journal of Medicinal Chemistry Covalent InhibitorsDrug TargetThiol ReactivityTyrosine KinaseMolecular Biology	2013	257
Preclinical Comparison of the Blood–brain barrier Permeability of Osimertinib with Other EGFR TKIs Nicola Colclough, Kan Chen, Peter Johnström, Clinical Cancer Research	2020	215
Opacity measurements in a hot dense medium T. S. Perry, S.J. Davidson, F. J. D. Serduke, Physical Review Letters EngineeringPhysicsOptical PropertiesSpectroscopyOpacity Measurements	1991	194
Expanding the Armory: Predicting and Tuning Covalent Warhead Reactivity Richard Lonsdale, Jonathan Burgess, Nicola Colclough, Journal of Chemical Information and Modeling	2017	173
Design and Synthesis of Novel Lactate Dehydrogenase A Inhibitors by Fragment-Based Lead Generation Richard A. Ward, C. Brassington, Alexander L. Breeze, Journal of Medicinal Chemistry Aldo-keto ReductaseMolecular BiologyLead IdentificationChemical BiologyMedicinal Chemistry	2012	169
Priming of the Neutrophil Respiratory Burst Involves p38 Mitogen-activated Protein Kinase-dependent Exocytosis of Flavocytochrome b 558-containing Granules Richard A. Ward, Michio Nakamura, Kenneth R. McLeish Journal of Biological Chemistry	2000	159

Page 1